Hospital academic status and value of care for nonmetastatic colon cancer

Journal of Oncology Practice

Volumn 11, Issue 3, 2015, Pages e304-e312

  Veenstra, Christine M ^a   Epstein, Andrew J ^a   Liao, Kaijun ^a   Griggs, Jennifer J ^a   Pollack, Craig E ^a   Armstrong, Katrina ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACADEMIC ACHIEVEMENT; AGED; ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; DISEASE SPECIFIC SURVIVAL; FAMILY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SCHOOL; MEDICARE; ONCOLOGY; PATIENT CARE; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL; VERY ELDERLY; AGE; CANCER REGISTRY; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HOSPITAL COST; KAPLAN MEIER METHOD; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STANDARDS; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; UNITED STATES;

ACADEMIC MEDICAL CENTERS; AGE FACTORS; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; FEMALE; HOSPITAL COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MEDICAL ONCOLOGY; MEDICARE; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; RETROSPECTIVE STUDIES; RISK FACTORS; SEER PROGRAM; TREATMENT OUTCOME; UNITED STATES;

EID: 84929664967     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2014.003137     Document Type: Article

References (30)

1. Siegel R, Desantis C, Jemal A: Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104-117, 2014
2. Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
3. Porter ME: What is value in health care? N Engl J Med 363:2477-2481, 2010
4. Epstein AM: US teaching hospitals in the evolving health care system. JAMA 273:1203-1207, 1995
5. Iezzoni LI: Major teaching hospitals defying Darwin. JAMA 278:520, 1997
6. Paulson EC, Mitra N, Sonnad S, et al: National Cancer Institute designation predicts improved outcomes in colorectal cancer surgery. Ann Surg 248:675-686, 2008
7. Birkmeyer NJ, Goodney PP, Stukel TA, et al: Do cancer centers designated by the National Cancer Institute have better surgical outcomes? Cancer 103:435-: 441, 2005
8. Ayanian JZ, Weissman JS: Teaching hospitals and quality of care: A review of the literature. Milbank Q 80:569-593, v, 2002
9. Taylor DH Jr, Whellan DJ, Sloan FA: Effects of admission to a teaching hospital on the cost and quality of care for Medicare beneficiaries. N Engl J Med 340:293-299, 1999
10. Knapp RM: Quality and safety performance in teaching hospitals. Am Surg 72:1051-1054; discussion 1061-1069, 1133-1148, 2006
11. Veenstra CM, Epstein AJ, Liao K, et al: The effect of care setting in the delivery of high-value colon cancer care. Cancer 120:3237-3244, 2014
12. Bynum JP, Bernal-Delgado E, Gottlieb D, et al: Assigning ambulatory patients and their physicians to hospitals: A method for obtaining population-based provider performance measurements. Health Serv Res 42:45-62, 2007
13. Gore JL, Saigal CS, Hanley JM, et al: Variations in reconstruction after radical cystectomy. Cancer 107:729-737, 2006
14. Elixhauser A, Steiner C, Harris DR, et al: Comorbidity measures for use with administrative data. Med Care 36:8-27, 1998
15. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444-1450, 1990
16. Moertel CG, Fleming TR, Macdonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990
17. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 122:321-326, 1995
18. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 345:939-944, 1995
19. Meropol NJ: Ongoing challenge of stage II colon cancer. J Clin Oncol 29:3346-3348, 2011
20. Moertel CG, Fleming TR, Macdonald JS, et al: Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 13:2936-2943, 1995
21. Le Voyer TE, Sigurdson ER, Hanlon AL, et al: Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 21:2912-2919, 2003
22. Gill S, Loprinzi CL, Sargent DJ, et al: Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and byhow much? J Clin Oncol 22:1797-1806, 2004
23. Compton CC, Fielding LP, Burgart LJ, et al: Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124:979-994, 2000
24. Benson AB 3rd, Schrag D, Somerfield MR, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408-3419, 2004
25. Kopetz S, Chang GJ, Overman MJ, et al: Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677-3683, 2009
26. Temple LK, Hsieh L, Wong WD, et al: Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol 22:3475-3484, 2004
27. Mayo SC, Heckman JE, Shore AD, et al: Shifting trends in liver-directed management of patients with colorectal liver metastasis: A populationbased analysis. Surgery 150:204-216, 2011
28. El Zouhairi M, Charabaty A, Pishvaian MJ: Molecularly targeted therapy for metastatic colon cancer: Proven treatments and promising new agents. Gastrointest Cancer Res 4:15-21, 2011
29. Kemeny NE: Treatment of metastatic colon cancer: "The times they are a-changing". J Clin Oncol 31:1913-1916, 2013
30. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer. gov/csr/1975-2011